Celltrion announced on the 13th that its three flagship autoimmune and oncology biologics have achieved the top prescription position in Europe, a key global market.

According to pharmaceutical market research firm IQVIA, Celltrion's autoimmune disease treatment 'Remsima (active ingredient infliximab)' product group (IV·SC) maintained its leading position with a 69% market share in Europe as of the second quarter of this year. Notably, it recorded high prescription performance and market share in major European countries such as the UK (87%) and Spain (80%). The subcutaneous injection form of infliximab, Remsima SC, also achieved significant results with 34% in France and 29% in Germany as a single prescription.

Another autoimmune disease treatment, 'Yuflyma (adalimumab)', continued its upward trend. It achieved a 26% market share in Europe, reaching the top prescription position for the first time since its local launch. Despite being launched approximately three years later than competitors in Europe, where being a first mover is advantageous for market dominance, it achieved remarkable results due to product competitiveness and the direct sales capabilities of the local subsidiary.

In the case of oncology drugs, 'Vegzelma (bevacizumab)', used for metastatic colorectal cancer and breast cancer treatment, achieved high prescription performance in key countries such as the UK (55%) and France (34%), with an average European market share of 24%, securing the top prescription position. 'Herzuma (trastuzumab)' and 'Truxima (rituximab)' maintained leading positions with market shares of 32% and 30%, respectively. This success is analyzed as a result of successful bids in major European countries such as Italy and Spain at the beginning of this year, leading to actual product prescriptions and reflecting in key indicators. Additionally, Celltrion's direct sales have strengthened its hospital and pharmacy network, expanding sales in retail distribution channels, which has positively impacted market share. Some evaluate that the enhancement of the product lineup is improving brand image and becoming visible in prescription performance.

Based on the performance of existing products, Celltrion plans to accelerate market dominance for newly launched follow-up products in the second half of this year. The chronic idiopathic urticaria treatment 'Omriclo (omalizumab)', launched as a first mover in Europe last September, is progressing smoothly, and follow-up products such as the ophthalmic disease treatment 'Idenzelt (aflibercept)' and the bone disease treatment 'Stoboclo-Osenbelt (denosumab)' are set to be launched within the year. The strategy is to maximize marketing synergy effects based on portfolio expansion by actively utilizing the network established through existing product sales.

A Celltrion representative stated, "In the highly competitive biosimilar market, our flagship products have achieved the top prescription position in Europe, demonstrating overwhelming performance against competing products, based on Celltrion's unique product competitiveness and direct sales capabilities. We will do our best to strengthen our sales capabilities in Europe so that the sales performance of existing products can spread to newly launched products, achieving both sales growth and profit improvement."

Popular News